secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001232524-25-000025
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Q1 revenues flat at $898M; GAAP net loss widens to $92.5M; updated guidance after Chimerix
--------------------------------------------------------------------------------

- GAAP net loss $92.5M ($1.52 loss/share) vs $14.6M loss in 1Q24; adjusted net income $105.2M ($1.68 EPS) vs $178.4M ($2.63).
- Xywav revenue $344.8M (+9% YoY), Epidiolex $217.7M (+10% YoY); Xyrem fell 42% to $37.2M.
- Affirmed 2025 total revenue guidance $4.15-4.40B; updated to reflect Chimerix acquisition and Xyrem settlements.
- Completed Chimerix acquisition in April; added dordaviprone; PDUFA Aug 18, 2025 for recurrent H3 K27M-mutant glioma.
- Submitted sNDA for Zepzelca in 1L ES-SCLC maintenance; positive CHMP opinion for zanidatamab in 2L BTC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/0001232524-25-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/jazz-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001232524-25-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer